Loading...

Molecular basis of pharmacotherapies for cognition in Down syndrome

Intellectual disability (ID) in Down syndrome (DS) ranges from low normal to severely impaired, and has a significant impact on the quality of life of the individuals affected and their families. Because the incidence of DS remains at approximately one in 700 live births and the life span is now >...

Full description

Saved in:
Bibliographic Details
Main Author: Gardiner, Katheleen J.
Format: Artigo
Language:Inglês
Published: 2009
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815198/
https://ncbi.nlm.nih.gov/pubmed/19963286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tips.2009.10.010
Tags: Add Tag
No Tags, Be the first to tag this record!